DURHAM, N.C., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), ("Scorpius", or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced a delay in its previously announced public offering. The Company has requested, and the NYSE has approved, a financial viability exception to the NYSE American shareholder approval rules that would allow it to proceed with the closing of an underwritten public offering. The Company intends to p ...

Scorpius (NYSEMKT:SCPX) stock is taking a beating on Wednesday after the company provided details on a public offering. Scorpius has announced that it will sell 12.5 million shares of SCPX stock in this public offering. The company has also priced these shares at $1 each. That will see it generate gross proceeds of $125 million from this offering. Additionally, underwriters have a 45-day option to acquire another 1.875 million shares of SCPX stock at the offering price. This could provide the company with a ...

财务预测 - 公司预计第二季度收入在300万美元至800万美元之间[11] - 公司预计第二季度经营亏损在860万美元至910万美元之间，税前净亏损在920万美元至970万美元之间[11] - 截至2024年6月30日，公司现金及现金等价物和短期投资约为150万美元[11] 业务收入 - 2024年上半年收入主要来自工艺开发业务，不包括2024年7月开始的微生物cGMP制造业务和预计在第三季度开始的细胞cGMP制造业务收入[12] - 公司预计cGMP制造合同的规模将普遍大于目前已签订的工艺开发合同[12]

DURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced that the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading suspension of the Company's common stock on the NYSE American. The NYSE Regulation staff determined that the Company's common stock was now trading above the threshold of low selling pric ...

DURHAM, N.C., July 24, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced that the Company expects to launch its first cGMP mammalian manufacturing campaign at its San Antonio manufacturing facility in the 3rd quarter of 2024. This milestone highlights the expansion of the Company's biomanufacturing capabilities, particularly in the field of mammalian cell culture pro ...

DURHAM, N.C., July 24, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced that the Company expects to launch its first cGMP mammalian manufacturing campaign at its San Antonio manufacturing facility in the 3rd quarter of 2024. This milestone highlights the expansion of the Company’s biomanufacturing capabilities, particularly in the field of mammalian cell culture pro ...

DURHAM, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the successful execution of its first current Good Manufacturing Practice (cGMP) microbial batches at its San Antonio manufacturing facility. This significant milestone marks the beginning of Scorpius’ support for manufacturing programs through clinical manufacturing, with aspirations for future ...

DURHAM, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the successful execution of its first current Good Manufacturing Practice (cGMP) microbial batches at its San Antonio manufacturing facility. This significant milestone marks the beginning of Scorpius' support for manufacturing programs through clinical manufacturing, with aspirations for future ...

DURHAM, N.C., July 17, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE:SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced that the Company's Board of Directors approved a 1-for-200 reverse stock split (the "Reverse Stock Split") of the Company's common stock (the "Common Stock"), to increase the selling price of the Company's Common Stock in order to regain compliance with the requirements and policies of the NYSE American. ...

DURHAM, N.C., July 17, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced that the Company’s Board of Directors approved a 1-for-200 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock (the “Common Stock”), to increase the selling price of the Company’s Common Stock in order to regain compliance with the requirements and policies of the NYSE ...